|Day Low/High||10.60 / 11.40|
|52 Wk Low/High||3.20 / 12.05|
Detailed Data to be Presented at AASLD in October
In recent trading, shares of Arbutus Biopharma Corp have crossed above the average analyst 12-month target price of $6.62, changing hands for $6.70/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
An Examination of the Rapidly Emerging field of mRNA Therapeutics in a Live Webinar hosted by the Nucleic Acid Drug Delivery Leader Arbutus Biopharma
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.